Blockchain Registration Transaction Record

NanoViricides' NV-387 Shows Promise as First Measles Treatment

NanoViricides announces NV-387, a potential first-ever Measles treatment, showing 130% survival increase in tests. A breakthrough in antiviral therapy.

The development of NV-387 by NanoViricides represents a significant breakthrough in antiviral therapy, especially for Measles, a disease that has seen a resurgence due to declining vaccine coverage. This news is crucial as it highlights the potential for a much-needed therapeutic option in the fight against Measles and other respiratory viral infections, offering hope for better outcomes in cases where vaccines are not an option or have failed to provide immunity.